Ser46-Phosphorylated MARCKS Is a Marker of Neurite Degeneration at the Pre-aggregation Stage in PD/DLB Pathology

eNeuro. 2018 Sep 4;5(4):ENEURO.0217-18.2018. doi: 10.1523/ENEURO.0217-18.2018. eCollection 2018 Jul-Aug.

Abstract

Phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) reflects neurite degeneration at the early stage of Alzheimer's disease (AD), before extracellular Aβ aggregates are histologically detectable. Here, we demonstrate that similar changes in MARCKS occur in Parkinson's disease (PD) and dementia with Lewy bodies (DLB) pathologies in both mouse models and human patients. The increase in the level of pSer46-MARCKS began before α-synuclein aggregate formation, at a time when human α-Syn-BAC-Tg/GBA-hetero-KO mice exhibited no symptoms, and was sustained during aging, consistent with the pattern in human postmortem brains. The results strongly imply a common mechanism of pre-aggregation neurite degeneration in AD and PD/DLB pathologies.

Keywords: Biomarker; MARCKS; degeneration; neurite; phosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism*
  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Animals
  • Disease Models, Animal
  • Female
  • Humans
  • Lewy Body Disease* / metabolism
  • Lewy Body Disease* / pathology
  • Male
  • Mice
  • Mice, Transgenic
  • Myristoylated Alanine-Rich C Kinase Substrate / metabolism*
  • Neurites / pathology*
  • Parkinson Disease* / metabolism
  • Parkinson Disease* / pathology
  • Phosphorylation

Substances

  • MARCKS protein, human
  • Marcks protein, mouse
  • Myristoylated Alanine-Rich C Kinase Substrate